NCCN Recommends First AI Prognostic Tool in Prostate Cancer
The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.
PC-3 human prostate cancer cells: © heitipaves - stock.adobe.com
The predictive and prognostic ArteraAI Prostate Test has been included in the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines for Prostate Cancer, making it the first artificial intelligence (AI)-enabled tool of its kind to be recommended for localized prostate cancer.1
“This recognition by the NCCN Guidelines underscores the importance of incorporating innovative tools like the ArteraAI Prostate Test into clinical practice, enabling clinicians and patients to make more informed decisions and personalize treatment strategies,” said Tim Showalter, MD, MPh, chief medical officer of ArteraAI, in a press release.
The guidelines noted the ArteraAI Prostate Test as having level 1B evidence supported by randomized controlled trials with narrow confidence intervals.1,2 Further, the test’s inclusion was based on a category 2A recommendation, representing a NCCN consensus of the tool’s validity for patients with prostate cancer.1
“ArteraAI’s inclusion within the guidelines reflects its growing significance in guiding optimal patient care pathways and represents a positive step forward in improving outcomes for individuals battling prostate cancer," said Felix Feng, MD, cofounder of ArteraAI and professor of radiation oncology, urology, and medicine at the University of California at San Francisco, in a press release.1
About ArteraAI Prostate Test
ArteraAI claims to identify 34% of patients with prostate cancer who can benefit from short-term hormone therapy, mitigating potential negative adverse effects of the therapy, including medical castration.3 In identifying patients who were biomarker-negative, the ArteraAI Prostate Test had a hazard ratio of 0.92 (95% CI, 0.59-1.43; P =.71; n = 1046). For patients who were biomarker-positive, the hazard ratio was 0.34 (95% CI, 0.19-0.63, P <.001; n = 673).
The ArteraAI Prostate Test also demonstrated superiority compared with NCCN standard methods in predicting long-term outcomes, including distant metastasis, biochemical failure, prostate cancer-specific survival, and overall survival. Findings published in 2022 showed that with a median follow-up of 11.4 years, ArteraAI’s models had between a 9.2% and 14.6% relative improvement over NCCN standard methods.4
REFERENCES:
1. ArteraAI announced as the first-and-only predictive test for therapy personalization in the 2024 NCCN Guidelines® for Prostate Cancer. News release. ArteraAI. March 4, 2024. Accessed March 5, 2024. https://tinyurl.com/5dn3t83e
2. Evidence-based medicine. Stony Brook University Libraries. Updated January 25, 2024. Accessed March 5, 2024. https://tinyurl.com/22s2jtuf
3. ArteraAI Prostate Test. Artera. Accessed March 5, 2024. https://tinyurl.com/3tsvdf3z
4. Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials [published correction appears in NPJ Digit Med. 2023 Feb 22;6(1):27]. NPJ Digit Med. 2022;5(1):71. Published 2022 Jun 8. doi:10.1038/s41746-022-00613-w
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
